Arcadia Biosciences, INC

Arcadia Biosciences discloses a discretionary bonus for CEO Thomas J. Schaefer for the 2025 fiscal year, alongside updated compensation details and the date for its 2026 annual meeting.

Arcadia Biosciences has closed a $4 million private placement of pre-funded warrants and investment options to institutional investors.

Arcadia Biosciences, Inc. has dismissed Deloitte & Touche LLP as its independent auditor and appointed Ramirez Jimenez International CPAs (RJI) as its successor.

Arcadia Biosciences announced its fourth-quarter and full-year 2025 financial results, highlighting Zola revenue growth, reduced operating expenses, and the termination of a proposed business combination.

Two directors, Albert D. Bolles, Ph.D., and Deborah Carosella, have resigned from Arcadia Biosciences' Board, effective February 4, 2026.

Arcadia Biosciences secured approximately $2.1 million in gross proceeds by inducing investors to exercise existing preferred investment options at a reduced price, issuing new options as an incentive.

Arcadia Biosciences reported a net income from continuing operations for Q3 2025, but a significant credit loss and declining cash reserves raise substantial doubt about its ability to continue as a going concern.

Arcadia Biosciences reported a significant net loss and substantial doubt about its ability to continue as a going concern, despite increased Zola coconut water sales.

Arcadia Biosciences reports a net income of $2.6 million for Q1 2025, driven by increased Zola coconut water sales and strategic asset sales, while expressing concerns about its ability to continue as a going concern.

Arcadia Biosciences reported its third quarter 2024 financial results, highlighting the sale of its GoodWheat brand and a focus on its Zola coconut water business.

Arcadia Biosciences reports a net income of $1.1 million for Q2 2024, driven by strategic asset sales and reduced operating expenses, while also noting concerns about its ability to continue as a going concern.

Arcadia Biosciences reported a net loss of $2.4 million for the first quarter of 2024 and expressed substantial doubt about its ability to continue as a going concern.

Arcadia Biosciences files an amendment to its 2024 annual report to include previously omitted information regarding directors, executive compensation, and corporate governance.

Arcadia Biosciences' 2024 10-K filing reveals a year of strategic asset sales, ongoing losses, and substantial doubt about its ability to continue as a going concern, all while pursuing a business combination with Roosevelt Resources LP.

Arcadia Biosciences has filed an amendment to its annual report to include previously omitted information regarding directors, executive officers, and corporate governance.

Arcadia Biosciences' 10-K filing outlines its capital structure, including common and preferred stock details, and various provisions designed to deter hostile takeovers.

Arcadia Biosciences announced the termination of its proposed business combination with Roosevelt Resources, prompting a renewed search for strategic alternatives.

Arcadia Biosciences reported an 11% increase in second-quarter 2025 revenues, primarily driven by Zola coconut water sales, but recorded a significant net loss due to a $4.5 million credit loss on a note receivable and the absence of prior year gains.

Chief Financial Officer of Arcadia Biosciences, Mark Kawakami, reports the acquisition of stock options.

Arcadia Biosciences CEO Thomas J. Schaefer reports the acquisition of stock options.

Arcadia Biosciences announces a 22% increase in revenue for Q1 2025, fueled by a 90% surge in Zola coconut water sales, alongside strategic moves to streamline operations and advance its merger with Roosevelt Resources.

Arcadia Biosciences and Roosevelt Resources have amended their Securities Exchange Agreement, extending the termination date to August 15, 2025, and modifying the share issuance terms for the all-stock transaction.

Arcadia Biosciences, Inc. announced its 2025 Annual Meeting of Stockholders to be held virtually on December 19, 2025, to vote on director elections, executive compensation, and auditor ratification.

Arcadia Biosciences has scheduled its annual stockholder meeting for June 25, 2024, and is seeking votes on director elections, auditor ratification, an equity incentive plan amendment, and executive compensation.

Arcadia Biosciences is holding its 2024 Annual Meeting virtually on June 25, 2024, to vote on director elections, auditor ratification, an equity incentive plan amendment, and executive compensation.

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 7.75% in Arcadia Biosciences, Inc., holding 159,390 shares as of March 31, 2026.

Arcadia Biosciences, Inc. has disclosed a beneficial ownership of 5.08% in Above Food Ingredients Inc., holding 2,738,574 shares of common stock.

Sabby Management, Sabby Volatility Warrant Master Fund, and Hal Mintz have reported a reduction in their passive beneficial ownership stake in Arcadia Biosciences, Inc. to 4.9% as of December 31, 2024.